This handout is for sickle cell disease (chronic management + acute crisis). Your care team identified this based on: vaso-occlusive pain crisis (ash 2020; nhlbi 2014).
Other reasons your team may use this plan: fever in scd (functional asplenia — sepsis until proven otherwise) (ash 2020); chest pain / dyspnea / hypoxia → acs workup (ash 2020); priapism >4h (ash 2020).
Take these medications exactly as prescribed. Do not stop or change a dose without talking to your provider.
| Medication | Starting dose | How | When | What it does |
|---|---|---|---|---|
| hydroxyurea | — | — | — | MSH NEJM 1995; BABY HUG; ASH 2020; foundation of DMT |
| l_glutamine | — | — | — | BEACON NEJM 2018 |
| crizanlizumab | — | — | — | SUSTAIN NEJM 2017 — STAND phase 3 FAILED; EU/UK revoked 2023–2024; clinical benefit questioned |
| exa_cel_casgevy | — | — | — | FDA approval Dec 2023; one-time CRISPR-edited autologous HSC |
| lovo_cel_lyfgenia | — | — | — | FDA approval Dec 2023; lentiviral β-globin |
Plan: Disease-modifying therapy (chronic)
Use these zones to know what to do based on how you feel.
Call 911 or go to the nearest emergency room right away if you have:
Health maintenance per NASCC 2024: vaccinations (penicillin prophylaxis ages <5), TCD, retinopathy screen, baseline echo, contraception/pregnancy planning, cognitive assessment, transition to adult care
Guideline: ASH 2020 SCD Guidelines (multiple Blood Advances) + NHLBI 2014 + NASCC 2024 Health Maintenance + ASH 2025 draft hydroxyurea